



## Correction: Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview

Christoph U. Correll<sup>1,2,3</sup> · Edward Kim<sup>4</sup> · Jennifer Kern Sliwa<sup>4</sup> · Wayne Hamm<sup>5</sup> · Srihari Gopal<sup>6</sup> · Maju Mathews<sup>6</sup> · Raja Venkatasubramanian<sup>6</sup> · Stephen R. Saklad<sup>7,8</sup>

Published online: 26 November 2024  
© The Author(s) 2024

**Correction:** *CNS Drugs* (2021) 35:39–59  
<https://doi.org/10.1007/s40263-020-00779-5>

In Fig. 2 of this article, two drug labels in the y axis were mislabeled, with aripiprazole monohydrate (AM) and aripiprazole lauroxil (AL) having swapped positions; the corrected Fig. 2 should have appeared as shown below.

The original article has been corrected.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

---

The original article can be found online at <https://doi.org/10.1007/s40263-020-00779-5>.

---

✉ Stephen R. Saklad  
Saklad@uthscsa.edu

- <sup>1</sup> Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
- <sup>2</sup> Division of Psychiatric Research, Zucker Hillside Hospital, Glen Oaks, NY, USA
- <sup>3</sup> Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany
- <sup>4</sup> Janssen Scientific Affairs, LLC, Titusville, NJ, USA
- <sup>5</sup> Janssen Scientific Affairs, LLC, Spring Hill, TN, USA
- <sup>6</sup> Janssen Research and Development, LLC, Titusville, NJ, USA
- <sup>7</sup> College of Pharmacy, Pharmacotherapy Division, The University of Texas at Austin, 7703 Floyd Curl Drive, MC 6220, San Antonio, TX 78229-3900, USA
- <sup>8</sup> Long School of Medicine, Pharmacotherapy Education and Research Center, UT Health San Antonio, San Antonio, TX 78229-3900, USA

**Fig. 2** Peak-to-trough plasma concentration ratios of oral and long-acting injectable antipsychotics at steady state [36, 118–121]. *AL* aripiprazole lauroxil, *AM* aripiprazole monohydrate, *ER* extended release, *LAI* long-acting injectable, *PP1M* paliperidone palmitate once monthly, *PP3M* paliperidone palmitate every 3 months, *qxw* every x weeks, *RLAI-MS* risperidone long-acting injection microspheres

